Search

Ultimately, implantable cardioverter-defibrillators (ICD) will one day be implantable like present pacemakers. However, due to the size of the pulse generator and the low defibrillation efficacy of monophasic shocks, only a few selected patients have been implanted transvenously-pectorally. Therefore, we have prospectively investigated whether a transvenous-pectoral approach is in general feasible with a new downsized ICD capable of delivering biphasic shocks. Out of 33 patients, 76% received a bipolar transvenous defibrillation lead system. In the first 13 consecutive patients, a randomized crossover study showed that this high efficacy was above all achieved by a superior defibrillation efficacy of the biphasic waveform in comparison to the monophasic waveform (69% vs. 23%; p = 0.03). Not a single patient could be defibrillated exclusively with the monophasic waveform. In a further 15 consecutive patients, a crossover study showed that a position of the transvenous anode within the Vena anonyma instead of the Vena cava superior is, in general, not superior (87% vs. 80%; p = 0.67). Only one patient could be exclusively defibrillated with the V. anonyma position. Intraoperatively, no complications occurred and all but one patient received a pectoral implantation of the pulse generator. Postoperatively, in five patients local complications related to the ICD system were seen; two needed a surgical revision. In two patients movements of the left shoulder joint were temporarily restricted. Thus, in the majority of patients a new downsized ICD capable of biphasic shocks can be implanted transvenously-pectorally like a pacemaker.

This study describes the placement of a newly designed implantable cardioverter defibrillator in a subpectoral device pocket using the incision for venous access in 16 patients undergoing implantation of an implantable cardioverter defibrillator with a nonthoracotomy lead system. The endocardial lead system consisted of a right atrial/superior vena cava defibrillation spring electrode and a right ventricular bipolar sensing/defibrillation electrode, inserted by cephalic venotomy or by puncturing of the subclavian vein. As a result of intraoperative testing using biphasic shocks the defibrillation threshold (DFT) had to be less than 24 J, otherwise an additional subcutaneous patch electrode was placed in the lateral chest wall near the cardiac apex through another incision. All patients received a nonthoracotomy lead system in combination with a subpectoral device placement. In 11 of 16 patients the endocardial leads alone were sufficient (DFT, 13.4 +/- 7.0 J), 5 of 16 patients (31%) required an additional subcutaneous patch electrode to achieve proper device function (DFT, 14.6 +/- 9.0 J). The operation lasted 93 +/- 20 minutes. This was a significant (p < 0.05) lower time consumption than standard nonthoracotomy approach combined with abdominal device placement (120 +/- 50 minutes). There were no postoperative complications. During follow-up period (average, 4 months), none of the patients reported major local symptoms, especially no device migration occurred. This approach, in contrast to an abdominal device placement, avoids another incision and subcutaneous tunneling of leads. In 11 of 16 patients defibrillator implantation by a single incision in the deltoideopectoral groove was possible.

Introduction: The defibrillation threshold (DFT) of a transvenous-subcutaneous electrode configuration is sometimes unacceptably high. To obtain a DFT with a sufficient safety margin, the defibrillation field can be modified by repositioning the electrodes or more easily by a change of electrode polarity. In a prospective randomized cross-over study, the effect of transvenous electrode polarity on DFT was evaluated., Methods and Results: In 21 patients receiving transvenous-subcutaneous defibrillation leads, the DFT was determined intraoperatively for two electrode configurations. Two monophasic defibrillation pulses were delivered in sequential mode between either the right ventricular (RV) electrode as common cathode and the superior vena cava (SVC) and subcutaneous electrodes as anodes (configuration I) or the SVC electrode as common cathode and the RV and subcutaneous electrodes as anodes (configuration II). In each patient, both electrode configurations were used alternately with declining energies (25, 15, 10, 5, 2 J) until failure of defibrillation occurred. The DFT did not differ between both configurations (18.3 +/- 8.2 J vs 18.9 +/- 8.9 J; P = 0.72). Eleven patients had the same DFT with both electrode configurations, 5 patients a lower DFT with the RV electrode as cathode, and 5 patients a lower DFT with the SVC as cathode. Four patients had a sufficiently low DFT (< or = 25 J) with only 1 of the 2 configurations., Conclusion: A change of electrode polarity of transvenous-subcutaneous defibrillation electrodes may result in effective defibrillation if the first electrode polarity tested fails to defibrillate. In general, neither the RV electrode nor the SVC electrode is superior if used as a common cathode in combination with a subcutaneous anodal chest patch.

Introduction: For current implantable defibrillators, the nonthoracotomy approach to implantation fails in a substantial number of patients. In a prospective randomized cross-over study the defibrillation efficacy of a standard monophasic and a new biphasic waveform was compared for different lead configurations., Methods and Results: Intraoperatively, in 79 patients receiving nonthoracotomy defibrillation leads, the defibrillation threshold was determined in the initial lead configuration for the mono- and biphasic waveform. In each patient, both waveforms were used alternately with declining energies (20, 15, 10, 5 J) until failure of defibrillation occurred. Three different initial lead configurations were tested in different, consecutive, nonrandomized patients using a bipolar endocardial defibrillation lead alone (A; n = 36) or in combination with a subcutaneous defibrillation patch (B; n = 24) or array (C; n = 19) lead. The lowest successful defibrillation energy with the biphasic waveform was less than, equal to, or higher than with the monophasic waveform in 64%, 28%, and 8% of patients, respectively, and on average significantly lower with the biphasic waveform for all three lead configurations (A: 11.3 +/- 4.4 J vs 14.5 +/- 4.5 J; B: 9.7 +/- 4.7 J vs 15.1 +/- 4.5 J; C: 7.9 +/- 4.5 J vs 12.4 +/- 4.9 J). Defibrillation efficacy at 20 J was significantly improved by the biphasic waveform (91% vs 76%)., Conclusion: In combination with nonthoracotomy defibrillation leads, the biphasic waveform of a new implantable cardioverter defibrillator showed superior defibrillation efficacy in comparison to the standard monophasic waveform. Defibrillation thresholds were improved for lead systems with and without a subcutaneous patch or array lead.

The role of programmed ventricular stimulation (PVS) in patients at high risk of sudden death related to idiopathic dilated cardiomyopathy (DCM) is still controversial. The possible reason is that most study series have been too small or that only a few patients had documented sustained ventricular tachyarrhythmias. This study therefore, looked at PVS performed in 102 patients with DCM and documented sustained ventricular tachycardia (VT; n = 63) or ventricular fibrillation (VF; n = 39). Sustained VT was induced in 27 of 63 patients (43%) with documented sustained VT and in 14 of 39 patients (36%) with documented VF (ns). VF was induced in nine patients (14%) with a history of sustained VT and in seven (18%) with a history of VF (ns). At a mean follow-up of 32 +/- 15 months, sudden death occurred in 14 (14%) patients, a rate similar in both patients with documented VT and VF (ns). Incidence of sudden death at 36 months was 6% in patients with inducible sustained VT/VF compared to 29% in patients without inducible VT/VF (P < 0.05). A favourable drug regimen (response to drug and no intolerable side effects) was obtained by serial drug testing in 25 of all 102 patients (25%). A cardioverter defibrillator (ICD) was implanted in 32 patients, in 63% of whom discharges were observed during 18 +/- 11 months of follow-up; only one patient (3%) died suddenly. Thus, in patients with DCM, there was no relationship between documented and inducible ventricular tachyarrhythmias, and initiation of sustained VT or VF had little prognostic value for the prediction of subsequent sudden death. Wherever antiarrhythmic drug therapy was of limited value, implantation of an ICD may improve the prognosis of these high risk patients.

Objectives: This study was done to provide information on the potential benefit of implantable cardioverter-defibrillator therapy regarding sudden and arrhythmia-related deaths and to examine whether such therapy improves survival., Background: Implantation of automatic cardioverter-defibrillators is reported to abort sudden cardiac death due to malignant tachyarrhythmias., Methods: Between 1989 and 1992, 107 patients were screened for implantation of a third-generation implantable cardioverter-defibrillator combined with endocardial leads. Mean age was 57 +/- 13 years and mean ejection fraction was 40 +/- 15%. Sudden death, total arrhythmia-related death and total cardiac death were compared with the occurrence of fast ventricular tachyarrhythmias (> 240 beats/min), assuming that most of these arrhythmias would have been fatal without treatment by the implantable cardioverter-defibrillator., Results: The surgical mortality rate was 2.7% in all 107 patients and 1% in the 99 patients who qualified for endocardial leads. During a follow-up period of 12 +/- 8 months, actuarial survival rate free of events at 6 months as well as at 12 and 18 months was 100% for sudden death, 97% for total arrhythmia-related death and 95% for total cardiac death. In contrast, after 6, 12 and 18 months, the rate of survival free of fast ventricular tachycardia was only 83%, 74% and 69%, respectively, and the rate of survival free of any ventricular tachyarrhythmia was only 59%, 49% and 40%, respectively., Conclusions: The outcome of patients treated with an implantable cardioverter-defibrillator and endocardial defibrillation leads is excellent. For many patients, this treatment is probably lifesaving.

The time of onset of 4,471 episodes of ventricular tachycardia (VT) or fibrillation (VF) in 40 of 65 patients with an implantable cardioverter-defibrillator (ICD) with endocardial defibrillation electrodes (group 1) and in 53 of 123 with epicardial defibrillation electrodes (group 2) was analyzed to examine whether the incidence of VT/VF immediately after surgery is greater than during further follow up and whether the site of lead placement exerts an influence on the occurrence of these arrhythmias. Actuarial survival rates free of VT/VF were 77, 65, and 54% at 1, 3 and 6 months, respectively, for group 1, and 84, 66 and 52%, respectively, for group 2. The probability of VT/VF was increased only during the first week after surgery; in that week, 12.8% of all patients had VT/VF, without significant differences between groups 1 and 2. Until the end of the first month, this percentage increased to 23%, whereas only 12 to 15% of patients had VT/VF during subsequent months. In 19 patients with third-generation devices capable of terminating tachycardias by overdrive pacing, 326 of 412 VT/VF episodes occurring in the first week after surgery were terminated by antitachycardia pacing, and only 86 had to be terminated by cardioversion or defibrillation. No postoperative exacerbation of inappropriate ICD therapies was observed in any group; 2 to 5% of patients per month received ICD therapies for atrial fibrillation or sinus tachycardia. Patients who received appropriate ICD therapies in the first week after surgery were at high risk of recurrence of VT/VF.(ABSTRACT TRUNCATED AT 250 WORDS)

Objectives: This study was conducted to assess the effectiveness of antitachycardia pacing modes and detection algorithms in patients with a new third-generation implantable cardioverter-defibrillator., Methods: Twenty-three of 42 consecutive patients had coronary artery disease, 14 had dilated cardiomyopathy, 2 had prior valve replacement and 3 had arrhythmogenic right ventricular dysplasia. The mean ejection fraction was 41 +/- 14%; there were 31 men (74%) and 11 women, with a mean age of 53 years. On the basis of preoperative and postoperative electrophysiologic studies, in 28 patients antitachycardia pacing was postoperatively programmed randomly as "burst" (66%) or autodecremental "ramp" (34%) stimulation with a first coupling interval of 81% of tachycardia cycle length and up to 8 sequences with 3 to 10 stimuli., Results: During a follow-up interval of 6.3 +/- 2.2 months, 15 patients were treated by antitachycardia pacing for a median of 6 (range 1 to 59) hemodynamically stable ventricular tachycardias (175 +/- 12 beats/min). In 5 patients, 22 ventricular tachycardias (9%) were not terminated by antitachycardia pacing but by cardioversion. Seven (3%) of these episodes accelerated (> 50 ms) during antitachycardia pacing. Syncope did not occur during these episodes. In seven patients initial antitachycardia pacing in cases of supraventricular tachycardias delayed charging and redetection prevented inappropriate discharges. Additional detection algorithms were programmed only after inappropriate therapy. The sudden "onset" and "sustained rate duration" criteria were programmed in three patients and the cycle length "stability" criteria in six patients, respectively. After activation of these detection algorithms only two of the seven patients had further inappropriate device discharges., Conclusions: Thus, antitachycardia pacing by this implantable cardioverter-defibrillator effectively and appropriately terminated 91% of hemodynamically stable ventricular tachycardias. Inappropriate device discharges were prevented in some patients by antitachycardia pacing and additional detection algorithms.

Technical improvements of third generation implantable cardioverter defibrillators (ICD) like antitachycardia pacing modalities lead to an extended use of ICDs, not only in patients with aborted sudden cardiac death, but also in patients with hemodynamically tolerable ventricular tachycardia. In addition, anticipated results of current prospective studies might indicate the prophylactic use of ICDs in patients with high risk for sudden cardiac death, but without documented ventricular tachyarrhythmias. This report reviews mortality and complications associated with the ICDs with epicardial defibrillation leads. Mortality is separated in cardiac death, sudden cardiac, arrhythmogenic "not so sudden" cardiac death, and overall mortality. Pulmonary complications and infections are related to the underlying disease and the surgical procedure. Device- and lead-related complications, high defibrillation thresholds, pacemaker interactions, inappropriate shocks, arrhythmic effects, syncope, and psychosocial problems are reported, respectively.

The case of a 30-year-old woman with polycystic disease of the kidneys and a large cyst in the interventricular septum is presented. The hypothesis of an echinococcal disease or of a cardiac manifestation of a polycystic disease was raised. The patient's history, serologic data, and the morphological aspect of the cyst did not give evidence for echinococcal disease before surgery. However, the postoperative pathological evaluation confirmed the diagnosis of a single echinococcal cyst. The presented case shows that even in cases without proven diagnosis of echinococcal disease and preexisting hereditary cysts in other organ systems, care should be taken during surgery to avoid anaphylaxis and preoperative spread of the parasite throughout the body.

Low-amplitude, high frequency components in the terminal QRS-complex (so-called late potentials) are thought to arise from diseased myocardial tissue that forms the "electrophysiologic substrate" for ventricular tachyarrhythmias. Recording of late potentials is now commercially available in several systems and may possibly become clinically routine in the near future. Increased attention has been given recently to heart rate variability as an indicator of conditions of the autonomic nervous system that might trigger ventricular tachyarrhythmias. The value of late potentials and heart rate variability for identification of patients at risk for developing life-threatening ventricular tachyarrhythmias is discussed, as are the other applications and limitations of both methods.

Unlabelled: To determine the effects and the underlying mechanisms of sudden rise of impedance during radiofrequency (RF) catheter ablation, 60 RF applications were delivered to isolated preparations of ventricular myocardium at three different power levels (mean: 3.7, 11.3, 19.3 watts). Pulse duration was 30 s, current voltage and catheter tip temperature were continuously monitored. Impedance rise occurred during 34 of 60 applications; the incidence of impedance rise increased at higher power levels. Impedance rise was significantly more often observed when the preparations were superfused with heparinized blood compared to saline solution (p less than 0.05). Catheter-tip temperature during radiofrequency application without impedance rise was significantly lower compared to applications with impedance rise (mean = 108 degrees C vs. 121 degrees C, p less than 0.01). The increase of catheter-tip temperature and maximal-tip temperature following impedance rise was significantly higher in blood when compared to saline solution (mean = +48 degrees C vs. +13 degrees C (p less than 0.001), Tmax: 121 degrees C vs. 245 degrees C). Following impedance rise, insulation defects of the electrode catheter and vaporized crater formation of the myocardium was often observed., Conclusions: During radiofrequency catheter ablation impedance rise occurs following overheating of the catheter electrode (greater than 110 degrees C). After impedance rise, catheter-tip temperature markedly increases. Insulation defects of the catheter and vaporized craters in the myocardium frequently occur after impedance rise. The results have important implications for the clinical use of RF-currents for catheter ablation; energy application should be immediately stopped after the occurrence of impedance rise.

We report two cases of licorice-induced arrhythmias. In both cases the ingestion of large amounts of licorice caused a marked hypokalemia. The importance of licorice-induced hypokalemia for the development of arrhythmias is underestimated from the small number of published cases. We conclude that patients with a predisposition for arrhythmias should avoid licorice candies.

The contrast between samples simulating musculoskeletal neoplasms and muscle or bone marrow achieved with FLASH sequences, was analysed in phantom studies and was compared with theoretically calculated contrast with and without correction for flip angle distribution over the slice profile. The contrast was correlated closer with the flip angle than with TR or TE. For delineation of the tumour from muscle, only a FLASH sequence with a large flip angle following intravenous administration of Gd-DTPA can be recommended, if a tumour shows a clear Gd-DTPA uptake. With all FLASH sequences analysed, no sufficient contrast between "tumour" without Gd-DTPA uptake and muscle was obtained. Maximal contrast between "tumour" and bone marrow was achieved with small flip angles; and an additional peak was noted with large flip angles and short TR. Experimentally measured T2*-dependent contrasts were nearly identical with theoretically calculated contrasts without correction of flip angle distribution. For calculation of T1-dependent contrasts, correction of the flip angle distribution over the slice profile was of high value.

1. Rapid inward sodium current (INa) was studied on intact rat papillary muscles and trabeculae excised from right or left ventricle using the loose-patch-clamp technique. All experiments were carried out at 25 degrees C. 2. Currents were recorded from patches with a large current density of mean 5.9 +/- 0.5 mA/cm2. 3. The current was reduced by tetrodotoxin (TTX) in a dose-dependent manner. The concentration of TTX producing half-maximal blockade of INa was 6.3 +/- 0.8 mumol/l. 4. Na+ current appeared upon depolarization at a threshold potential of about -55 mV and reached its maximum at about -20 mV. 5. Kinetic data were evaluated using the Hodgkin-Huxley model. 6. Time constants of activation (tau m) were estimated using single-pulse and tail-current measurements. They had a maximum of about 0.4 ms near the threshold potential and declined at more positive and at more negative potentials to values near 0.1 ms. 7. Two time constants were necessary to describe inactivation. Both time constants had their maximal values of 135 +/- 8.1 and 29.1 +/- 5.9 ms at about -80 mV and decreased towards 4 and 0.5 ms at potentials positive to -20 mV.

A case of choledocho-gastric fistula resulting from a cholangio-carcinoma is reported. The final diagnosis was obtained by ERCP, whereas CT, barium examination, and gastroscopy initially did not allow a conclusive diagnosis. The only clinical finding was epigastric pain. Choledocho-gastric fistula is extremely rare.